Your trusted destination for CME, CPD & Medical Education across the Middle East.
King Faisal Specialist Hospital & Research Centre
Dr. Sabah Alaklabi, MD is a Saudi Consultant Medical Oncologist specializing particularly in breast cancer. She is based at King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, where she is affiliated with the Breast Cancer Centre, Medical Oncology Department, Cancer Centre of Excellence. She also has an academic affiliation with the College of Medicine, Alfaisal University.
Dr. Alaklabi obtained her medical degree from King Saud University College of Medicine in Riyadh, Saudi Arabia. She subsequently completed her Internal Medicine residency at the University of Virginia Medical Center in the United States and then completed a Medical Oncology fellowship at Roswell Park Comprehensive Cancer Center in Buffalo, New York.
Her training in the United States provided specialist experience in contemporary cancer management and clinical research, after which she returned to Saudi Arabia and developed her clinical and academic career at KFSHRC.
Dr. Alaklabi's principal clinical and research focus is breast oncology. Her work encompasses the management of:
Her research has included real-world outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer and treatment approaches for patients with metastatic TNBC carrying germline BRCA mutations.
Dr. Alaklabi has an active international research profile. Her publications include research in breast cancer treatment, immunotherapy and cancer therapeutics.
One of her notable publications examined real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast cancer, published in JCO Oncology Practice. Her affiliations were listed as both Roswell Park Comprehensive Cancer Center and King Faisal Specialist Hospital & Research Center.
She also co-authored research examining treatment strategies for metastatic triple-negative breast cancer with germline BRCA mutations.
Her research has additionally extended beyond breast cancer. She has contributed to work involving immunotherapy for malignant peritoneal mesothelioma and gastroenteropancreatic neuroendocrine tumors, reflecting broader expertise in medical oncology.
Dr. Alaklabi is particularly important to your Saudi Breast Cancer Expert Consensus Conference research.
She was the lead author and corresponding author of the major publication “Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi Arabia.” The consensus brought together Saudi oncology experts to develop recommendations for the management of early and metastatic breast cancer.
